Gilead Sciences stock pre-market at EUR 130.93: minus 0.18 percent
Published on 10/08/2026 at 08:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock is at EUR 130.93 in pre-market trading at Lang & Schwarz at 8:12 a.m. CEST on October 8, 2026. The price is down 0.18 percent against EUR 131.16, the prior close at Lang & Schwarz on October 7, 2026.
Pre-market trading
Lang & Schwarz shows a bid of EUR 130.80 and an ask of EUR 131.06 for Gilead Sciences. The Xetra session is scheduled to begin at 9:00 a.m. CEST. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
Recent company developments
On September 16, 2026, Gilead Sciences said it had expanded six royalty-free voluntary licensing agreements to include investigational once-yearly lenacapavir for HIV prevention. The agreements cover 120 high-incidence countries and are intended to support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 trial continues. The company said the once-yearly product remains investigational and has not been approved by a regulatory authority.
On September 8, 2026, Business Wire reported that Gilead had opened a 182,000-square-foot research center at its Foster City headquarters. The center brings together oncology, inflammation and research data science teams and is designed to support approximately 325 employees, including 260 laboratory scientists. The facility forms part of Gilead’s broader $32 billion U.S. investment in research, development and manufacturing through 2030.
